What lies ahead for vaccines

Cohort analysis shows the rate of RSV hospitalizations among children up to 5 years old skyrocketed in 2021—and then nearly doubled again in 2022—compared to pre-pandemic rates.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Of the 600,238 bivalent vaccine doses administered by all providers in the study period, 35,114 (5.9%) were done so by FRPP partners.

New data demonstrates protection against new variants.